Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") on April 27, 2017. The filing details a material definitive agreement involving a private placement of securities and the rescheduling of the company's annual stockholders meeting.
Key Financial Metrics and Transaction Details
The filing reports a capital raise transaction rather than standard operating financial metrics (revenue, profit, or cash flow are not provided in this document).
- Total Investment: $5,000,000 raised from Armistice Capital Master Fund Ltd.
- Common Stock Issued: 2,345,714 shares at $0.35 per share (approx. 19.99% of pre-closing outstanding shares).
- Preferred Stock Issued: 4,179 shares of Series A Convertible Preferred Stock (convertible into 11,940,000 common shares).
- Warrants Issued: Warrants to purchase up to 14,285,714 shares at an exercise price of $0.40 per share.
- Transaction Costs: $350,000 fee payable to Maxim Group LLC.
- Use of Proceeds: Preparation for clinical trials of product candidates CERC-501 and CERC-611, working capital, and general corporate purposes.
Material Changes and Corporate Actions
The filing outlines significant changes to the company's capital structure and governance:
- Board Representation: The Purchaser is entitled to elect two directors if they maintain at least 13% beneficial ownership, or one director if they maintain at least 10%.
- Preferred Stock Rights: Series A Preferred Stock holders have specific veto rights over liquidation, amendments to charter, issuance of senior securities, and debt creation (limited to $250,000).
- Meeting Reschedule: The 2017 Annual Meeting of Stockholders, originally scheduled for May 12, 2017, has been postponed to June 30, 2017 to allow for a vote on the private placement approval required by NASDAQ rules.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to advance clinical trials for CERC-501 and CERC-611. Key contingencies and risks include:
- Stockholder Approval: The conversion of Series A Preferred Stock and the exercise of Warrants are contingent upon approval by the Company's stockholders at the rescheduled meeting.
- Voting Restrictions: Holders of the common stock purchased in this private placement cannot vote on the approval of the private placement itself under NASDAQ rules.
- Regulatory Compliance: The securities were issued under Rule 506 of Regulation D and have not been registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the outcome of the stockholder vote scheduled for June 30, 2017, regarding the conversion of Series A Preferred Stock and Warrants.
- Confirm the final dilution impact once the Series A Preferred Stock converts into 11,940,000 shares and warrants are potentially exercised.
- Review the definitive proxy statement for the rescheduled annual meeting to understand the full scope of the proposal.
- Monitor the company's cash runway and progress toward initiating clinical trials for CERC-501 and CERC-611.
- Check for any subsequent filings regarding the $350,000 fee paid to Maxim Group LLC and its impact on net proceeds.